PONV

Remimazolam as an Alternative to Propofol in Oral Surgeries

Retrieved on: 
Monday, January 29, 2024
BSI, BIS, Patient, Heart rate, Bradycardia, Intubation, Incidence, EEG, DDS, Fentanyl, Consciousness, PONV, Propofol, Delirium, Remimazolam, Oral and maxillofacial surgery, Movement, Comparison, PSI, Doctor of Philosophy, Arousal, Remifentanil, Hypotension, Vomiting, Blood pressure, Tsurumi University, Dentistry

LAWRENCE, Kan., Jan. 29, 2024 /PRNewswire-PRWeb/ -- Anesthesia Progress – Propofol has been a widely used intravenous sedative for oral and maxillofacial surgeries because of advantages like less postoperative nausea and vomiting (PONV), no air pollution issues, a fast, clean emergence profile, and less emergence delirium. However, propofol has some significant downsides, including cardiovascular depression, injection pain, high fat content, and not being water-soluble. Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential. But is remimazolam as safe and effective as propofol?

Key Points: 
  • Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential.
  • The results of this study show that remimazolam could be considered a suitable alternative to propofol.
  • They go on to note that "remimazolam appears to be a safe alternative to propofol for providing intubated general anesthesia for oral and maxillofacial surgery procedures."
  • Full text of the article, "Comparison of Remimazolam and Propofol for Intubated General Anesthesia for Oral and Maxillofacial Surgery," Anesthesia Progress, Vol.

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

Retrieved on: 
Wednesday, December 6, 2023
Science, Food, Amisulpride, Nausea, MD, Incidence, PONV, Patient, Vomiting, CMS, Pharmaceutical industry

-- Unique J-code for Barhemsys (J-0184) from CMS effective on January 1, 2024 --

Key Points: 
  • The conference is sponsored by the New York State Society of Anesthesiologists and is a global platform for presenting anesthesia’s latest science and technologies.
  • “PONV contributes to prolonged post-anesthesia care unit and hospital stays and is distressing to patients and healthcare providers,” stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals.
  • This analysis details pooled data on nausea-related outcomes from two Phase III trials.
  • We believe Barhemsys presents an opportunity for a much-needed therapeutic option for these patients,” concluded Dr. Greenberg.

WAT Medical Joins World's Largest Boat Show

Retrieved on: 
Wednesday, December 13, 2023
Vomiting, Wang, Health Canada, TGA, NMPA, Electronics, Patient, Multimedia, Ohio State University, FDA, CE, Anesthesiology, University, Nausea, Trial of the century, Motion sickness, Motion, PONV, Vagus nerve, Amazon

VANCOUVER, BC, Dec. 13, 2023 /PRNewswire/ -- Discover Boating Miami International Boat Show (DBMIBS) is the world's largest boat and yacht show.

Key Points: 
  • VANCOUVER, BC, Dec. 13, 2023 /PRNewswire/ -- Discover Boating Miami International Boat Show (DBMIBS) is the world's largest boat and yacht show.
  • WAT Medical is a Canadian company that develops wearable medical technologies.
  • WAT Medical has partnered with VIKAND since the 2019 Seatrade Cruise Global conference to further expand EmeTerm's market.
  • British Journal of Anesthesiology
    View original content to download multimedia: https://www.prnewswire.com/news-releases/wat-medical-joins-worlds-larges...
    SOURCE WAT Medical Enterprise Ltd.

Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS

Retrieved on: 
Monday, October 23, 2023
FDA, Level 2, Amisulpride, Therapy, Government, Vomiting, MD, Medicare Advantage, PONV, Senior, Centers for Medicare & Medicaid Services, Healthcare Common Procedure Coding System, Interim, Hospital, Patient, Health insurance, Pharmaceutical industry, Medicare, Eagle

WOODCLIFF LAKE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code and granted transitional pass-through payment status for Barhemsys (amisulpride) injection. The new Healthcare Common Procedure Coding System (“HCPCS”) Level II code (“J-code”) is J-0184 “Injection, amisulpride, per 1 mg” and will be effective on January 1, 2024, replacing the C-code (C-9153), which will be discontinued. Beginning October 1, 2023, Barhemsys became eligible for separate reimbursement outside of the surgical bundled payment in both the ambulatory surgery center (“ASC”) and hospital outpatient department (“HOPD”) care settings.

Key Points: 
  • -- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access --
    WOODCLIFF LAKE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code and granted transitional pass-through payment status for Barhemsys (amisulpride) injection.
  • Beginning October 1, 2023, Barhemsys became eligible for separate reimbursement outside of the surgical bundled payment in both the ambulatory surgery center (“ASC”) and hospital outpatient department (“HOPD”) care settings.
  • “Receiving pass-through status, as well as a J-code, is an ideal combination that will facilitate patient access to this important therapeutic,” stated Scott Tarriff, President and Chief Executive Officer of Eagle.
  • The granting of pass-through status helps streamline the reimbursement process and facilitates patient access to Barhemsys.

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance

Retrieved on: 
Thursday, June 15, 2023
Acacia, Maintenance, Food and Drug Administration Safety and Innovation Act, QIDP, Bronchopneumonia, Marketing, Food, Eagle, Progress, GAIN, Vomiting, Acquisition, Patent, PONV, Patient, Physician, NCE, Nursing, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pemetrexed, Tariff, Safety, Breast cancer, Pharmaceutical industry, Remimazolam

“As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products. Through our well-trained and experienced sales force -- made up of 50 reps on the hospital side of the business and 25 focused on oncology -- for the quarter to date, Barhemsys® and Byfavo® have already topped the sales number posted in the first quarter of 2023, and PEMFEXY® has achieved an 18% market share in early Q2. We are pleased to see these two assets gaining uptake in the hospital and reflecting the value we saw when we originally decided to make the acquisition,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

Key Points: 
  • WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance.
  • “As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products.
  • Eagle anticipates continued growth in net sales of PEMFEXY in the remainder of 2023 as compared to 2022.
  • Guidance: The Company reaffirms previously provided 2023 full-year guidance.

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
Prescription Drug User Fee Act, Centers for Medicare & Medicaid Services, Marketing, New Drug Application, Meloxicam, Center for Medicare and Medicaid Innovation, Vomiting, Medicare, Net, Aprepitant, Shanda, Comparables, Bupivacaine, Patient, PONV, Investment, SAN, Heron, PDUFA, Webcast, Growth, Research, Therapy, Video game, Management, Pharmaceutical industry, Internet service provider, Cryptocurrency

SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.

Key Points: 
  • SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.
  • First quarter 2023 net product sales grew 26% to $29.6 million, compared to the first quarter of 2022.
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three months ended March 31, 2023 was $3.5 million.
  • Net product sales of APONVIE for the three months ended March 31, 2023 were $0.3 million.

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

Retrieved on: 
Thursday, March 23, 2023
Centers for Medicare & Medicaid Services, Pharming, New Drug Application, Meloxicam, Center for Medicare and Medicaid Innovation, Pain, Vomiting, Medicare, Net, Aprepitant, Shanda, Bupivacaine, Hospital, Patient, PONV, Investment, SAN, Heron, PDUFA, Webcast, Nausea, Growth, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Video game, Pharmaceutical industry, Cryptocurrency

SAN DIEGO, March 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and twelve months ended December 31, 2022 and highlighted recent corporate updates.

Key Points: 
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2022 were $3.9 million and $10.2 million, respectively.
  • Net product sales of ZYNRELEF for the three and twelve months ended December 31, 2021 were $0.8 million and $2.9 million, respectively (ZYNRELEF was launched July 1, 2021).
  • We currently expect first quarter 2023 ZYNRELEF demand unit sales to increase approximately 10% over the prior quarter.
  • Since launch on July 1, 2021 through December 31, 2022, 793 unique accounts purchased ZYNRELEF with 90% of those accounts reordering the product.

Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults

Retrieved on: 
Monday, March 6, 2023
MD, Woman, IV, Physician, Milk, SAN, Pharming, Headache, Brain, Aprepitant, Pregnancy, Hormone, Pain, Vomiting, Therapy, Patient, Heron, Plasma, Cochrane, Food, Food and Drug Administration, PONV, Allergy, FDA, Warfarin, Constipation, Tell, Intrauterine device, Dizziness, Vitamin, Fatigue, Condom, Sales, Pharmaceutical industry, Birth control

SAN DIEGO, March 6, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous (IV) use in adults for the prevention of PONV.

Key Points: 
  • Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to the current standard-of-care, IV ondansetron.
  • "This launch supports our ongoing commitment to delivering innovative solutions that improve the postoperative experience by addressing the two most common concerns after surgery, postoperative pain with ZYNRELEF® and postoperative nausea and vomiting with APONVIE."
  • The launch of APONVIE will now allow providers to prevent PONV without the limitations of the current oral route of administration.
  • Report side effects to Heron at 1-844-437-6611 or to the Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov/medwatch .

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

Retrieved on: 
Monday, January 9, 2023
Food, Therapy, Aprepitant, Regulation of tobacco by the U.S. Food and Drug Administration, Vomiting, SAN, Elective surgery, Shanda, PONV, Patient, Growth, FDA, Heron, Pharming, CMS, New Drug Application, CINV, Beauty salon, Pharmaceutical industry, Video game

SAN DIEGO, Jan. 9, 2023 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today highlights progress in its acute care and oncology care franchises.

Key Points: 
  • Full-Year 2022 Net Product Sales: Preliminary full-year 2022 net product sales for ZYNRELEF were approximately $10.1 million.
  • Fourth-Quarter 2022 Net Product Sales: Preliminary fourth-quarter 2022 net product sales for the oncology care franchise were approximately $25.3 million.
  • Full-Year 2022 Net Product Sales: Preliminary full-year 2022 net product sales for the oncology care franchise were approximately $96.6 million versus guidance of $93 million to $95 million.
  • Full-Year 2023 Net Product Sales Guidance: Heron expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates

Retrieved on: 
Tuesday, November 8, 2022
Food, RA, NDA, New Drug Application, Safety, Analgesic, Pharming, Growth, HEC, Webcast, Nausea, Achievement, News, FDA, Patient, Investor relations, Company, Granisetron, Compliance, Private Securities Litigation Reform Act, SAN, MEC, AC, Ankle, Health Canada, PONV, Cancer, Cyclophosphamide, Forward-looking statement, Drug discovery, COVID-19, Antiemetic, Regulation of tobacco by the U.S. Food and Drug Administration, Aprepitant, Net, Human, Pain, 3D ultrasound, Surgical incision, Elective surgery, Boxed warning, Vomiting, Investment, Foot, Head, Hospital, Nasdaq, Heron, U.S. Securities and Exchange Commission, Bupivacaine, Meloxicam, Therapy, Pharmaceutical industry, Platinum, Beauty salon, Aquaculture, Video game

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2022 and highlighted recent corporate updates.

Key Points: 
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and nine months ended September 30, 2022 were $2.7 million and $6.3 million, respectively.
  • Net product sales of ZYNRELEF for both the three and nine months ended September 30, 2021 were $2.1 million (ZYNRELEF was launched July 1, 2021).
  • The APONVIE (aprepitant) injectable emulsion NDA was approved by the U.S. Food and Drug Administration (FDA) on September 16, 2022.
  • 2022 Oncology Care Franchise Net Product Sales Guidance: Heron currently expects full-year 2022 net product sales for the oncology care franchise of $93 million to $95 million.